<DOC>
	<DOCNO>NCT01939730</DOCNO>
	<brief_summary>The goal clinical research study see use drug Rituximab ( IDEC-C2B8 ) Granulocyte-macrophage colony-stimulating factor ( GM-CSF ) ( Leukine ) together well use rituximab alone treat follicular B-cell lymphoma . The safety treatment also study .</brief_summary>
	<brief_title>Rituximab + GM-CSF Patients With Follicular B-Cell Lymphoma</brief_title>
	<detailed_description>Rituximab seek help destroy cancer cell . GM-CSF stimulate body produce white blood cell . Before treatment start , patient complete exam , include blood urine test . A chest x-ray CT scan MRI scan abdomen pelvis do measure tumor . Bone marrow lymph node sample take . Women able child must negative blood pregnancy test . Patients study receive rituximab GM-CSF . The combined treatment last 8 week . Rituximab give needle vein 3-6 hour week . GM-CSF give needle skin 3 time week . The first 3 dos usually give 1 hour rituximab dose . In selected case , GM-CSF start 1 week 1 day rituximab . Patients may also receive drug acetaminophen ( Tylenol ) diphenhydramine hydrochloride ( Benadryl ) 30-60 minute dose rituximab . This do ease side effect . Patients may need stay clinic 2 hour rituximab give . If combine Rituximab GM-CSF treatment cause severe side effect , treatment may stop . During study , blood test do rituximab treatment first fourth rituximab treatment . About 2 6 teaspoon blood draw test . A physical exam urine test do fourth rituximab treatment . After treatment do , patient complete exam , include blood test week 4 week 2 , 3 , 6 , 9 , 12 , 18 , 24 month . A CT scan MRI scan abdomen pelvis also do 2 , 3 , 6 , 9 , 12 , 18 , 24 month . Bone marrow sample take 2 , 3 , 12 month . Some patient may also bone marrow sample take year . A large needle use take bone marrow sample . This investigational study . GM-CSF rituximab approve commercial use FDA . As many 40 patient take part study . All treat outpatient . The study take place University Texas ( UT ) MD Anderson Cancer Center ( MDACC ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Histologically confirm follicular Bcell lymphoma . This include relapsed patient , prior rituximab therapy , previously untreated patient . Previously untreated patient make aware high priority protocol combination chemoimmunotherapy protocol , decline , enter protocol . 2 . Males female , 18 year old ; expect survival =/ &gt; 4 month ; performance status 0 , 1 2 . 3 . Demonstrable monoclonal cluster differentiation antigen 20 ( CD20 ) positive Bcell population . 4 . Acceptable hematologic status include : i. hemoglobin ( Hgb ) =/ &gt; 8.0 gm/dL ii . White blood count ( WBC ) =/ &gt; 3.0 x 10^3/mm^3 ( x 10^9/L ) iii . Absolute granulocyte count =/ &gt; 1.5 x 10^3/mm^3 iv . Platelet count =/ &gt; 75 x 10^3/mm^3 e. Adequate renal function ( serum creatinine â‰¤ 2mg/dl ) 1. presence Central Nervous System ( CNS ) Lymphoma 2. chronic lymphocytic leukemia ( CLL ) 3. small lymphocytic lymphoma 4. therapy prior 3 week ( 6 week nitrosourea ; 6 month Bone Marrow Transplantation ( BMT ) ) 5. patient receive prior rituximab antiCD20 therapy 6. serious nonmalignant disease , malignancy 7. active infection 8. history HIV infection pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Follicular B-Cell Lymphoma</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Sargramostim</keyword>
	<keyword>Leukine</keyword>
</DOC>